## Correct Answer: A. Medullary thyroid carcinoma Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy arising from parafollicular C cells of the thyroid. The pathognomonic histological finding is **amyloid deposition**, which represents amyloid-A protein derived from calcitonin and its precursor procalcitonin. This amyloid is Congo red-positive and shows apple-green birefringence under polarized light—a diagnostic hallmark. The clinical presentation of neck mass with odynophagia and dyspnea reflects local invasion and mass effect. MTC accounts for 3–5% of thyroid cancers in India. It secretes excessive calcitonin (diagnostic marker: serum calcitonin >100 pg/mL), causing systemic symptoms. Importantly, MTC is associated with MEN 2A and MEN 2B syndromes in ~25% of cases (RET proto-oncogene mutations), making genetic screening essential in Indian families. The amyloid deposition distinguishes MTC from all other thyroid malignancies, which do not produce calcitonin-derived amyloid. Treatment involves total thyroidectomy with central neck dissection; prognosis depends on stage and calcitonin doubling time. ## Why the other options are wrong **B. Papillary thyroid carcinoma** — Papillary carcinoma is the most common thyroid malignancy (80% of cases) but does NOT produce amyloid. Histology shows papillary architecture with Orphan Annie eye nuclei and psammoma bodies—not amyloid deposition. This is a classic NBE trap: students may confuse 'thyroid cancer + neck mass' with papillary carcinoma, ignoring the amyloid clue. **C. Anaplastic thyroid carcinoma** — Anaplastic carcinoma is highly aggressive and presents with rapid dyspnea and dysphagia, mimicking the clinical picture. However, histology shows spindle cells, giant cells, and necrosis—NOT amyloid. Amyloid deposition is not a feature of anaplastic carcinoma, making this a clinical red herring. **D. Follicular thyroid carcinoma** — Follicular carcinoma presents as a thyroid nodule but lacks amyloid deposition. Histology shows follicular architecture with capsular/vascular invasion. It does not produce calcitonin or calcitonin-derived amyloid, eliminating this option despite similar epidemiology to other differentiated thyroid cancers. ## High-Yield Facts - **Amyloid deposition** (Congo red-positive, apple-green birefringence) is pathognomonic for medullary thyroid carcinoma and derived from calcitonin/procalcitonin. - **Serum calcitonin >100 pg/mL** is the diagnostic marker for MTC; calcitonin doubling time predicts prognosis. - **MEN 2A/2B association** occurs in ~25% of MTC cases due to RET proto-oncogene mutations; genetic screening is mandatory in Indian families. - **Parafollicular C-cell origin** distinguishes MTC from follicular-derived thyroid cancers (papillary, follicular, anaplastic). - **Total thyroidectomy + central neck dissection** is the standard surgical treatment; external beam radiotherapy for advanced/recurrent disease. ## Mnemonics **MTC = Calcitonin + Amyloid** Medullary = C-cell (parafollicular) → Calcitonin production → Amyloid deposition. Remember: MTC is the ONLY thyroid cancer that makes amyloid. **MEN 2 + MTC Rule** MTC is part of MEN 2A (medullary thyroid + pheochromocytoma + hyperparathyroidism) and MEN 2B (medullary thyroid + pheochromocytoma + mucosal neuromas). Always screen RET gene in MTC patients. ## NBE Trap NBE pairs 'thyroid cancer + neck mass + dyspnea' with papillary carcinoma (the most common type) to lure students away from the amyloid clue. The discriminating histological finding (amyloid) is the key to avoiding this trap. ## Clinical Pearl In Indian practice, any thyroid cancer patient with elevated serum calcitonin and amyloid on biopsy should trigger immediate RET genetic testing and screening of first-degree relatives for MEN 2 syndrome—early identification of RET mutations allows prophylactic thyroidectomy in children, dramatically improving survival. _Reference: Robbins Ch. 8 (Endocrine System); Harrison Ch. 375 (Thyroid Malignancy)_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.